Management is buying/committing capital at a price it says the market itself just set against it — cheapness measured ag
The model's full reasoning — Q3 2023 call → NOWe need to determine if management describes deliberately taking on more of its own economic exposure because it believes the outside world is mispricing what it already has. The key elements: (1) a mispricing anchored to something concrete, and (2) the company is acting on it with real resources already in motion. Looking at the transcript, management discusses the FDA denial of De Novo classification for breast cancer indication. They filed an appeal. They talk about the comparator issue. They mention that the FDA's decision has no effect on other indications. They talk about sales growth, distribution expansion, etc. But there is no mention of the company buying back shares, insiders buying, acquiring assets, or any action that increases its claim on underpriced value. They are not discussing that the market is undervaluing the company. They are not talking about repurchasing shares or anything like that. They are just discussing operational progress and regulatory matters. There is no mention of mispricing or acting on it. So the answer is NO. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CTHR | Charles & Colvard, Ltd. | Q1 2023 | 2022-11-06 | F |
| SBGI | Sinclair Broadcast Group, Inc. | Q3 2022 | 2022-11-02 | C |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
TWO · Q2 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the mispricing to concrete, verifiable levels: mortgage spreads at “historically wide” levels (125–150 bp ZV/OAS, far above the non-QE average and the March 31 levels), RMBS coupons now trading at a wide range (2 %–5.5 %) with 300 bp “out-of-the-money” low-coupon pools and 97 bp OAS–ZV spread differential on higher-coupon names.
ESEA · Q4 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the undervaluation claim to a concrete, verifiable figure: their own estimate of the fleet’s market value at $666 million (derived from charter-adjusted values and market changes, incorporating the Aegean Express incident), which produces a net asset value of $344 million or >$48 per share.
WD · Q2 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the undervaluation claim to a concrete benchmark: CoStar trades at ~30x EBITDA while W&D trades at under 10x despite identical revenue and EBITDA growth rates over 5–10 years. They explicitly state there is “plenty of multiple expansion available to W&D.